title: Treatment of chronic kidney diseases with histone deacetylase inhibitors.
abstract: Histone deacetylases (HDACs) induce deacetylation of both histone and non-histone proteins and play a critical role in the modulation of physiological and pathological gene expression. Pharmacological inhibition of HDAC has been reported to attenuate progression of renal fibrogenesis in obstructed kidney and reduce cyst formation in polycystic kidney disease. HDAC inhibitors (HDACis) are also able to ameliorate renal lesions in diabetes nephropathy, lupus nephritis, aristolochic acid nephropathy, and transplant nephropathy. The beneficial effects of HDACis are associated with their anti-fibrosis, anti-inflammation, and immunosuppressant effects. In this review, we summarize recent advances on the treatment of various chronic kidney diseases with HDACis in pre-clinical models.
authors.affiliation: Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Na
authors.initials: N
authors.lastname: Liu
authors.affiliation: Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine Shanghai, China ; Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University Providence, RI, USA.
authors.forename: Shougang
authors.initials: S
authors.lastname: Zhuang
keywords: chronic kidney diseases; histone deacetylases; renal fibroblasts; renal fibrosis